Novel methods of type 1 diabetes treatment

Discovery Medicine

Volumn 17, Issue 96, 2014, Pages 347-355

  Jayaraman, Sundararajan ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; T LYMPHOCYTE RECEPTOR; HISTONE; MOLECULAR LIBRARY;

ARTICLE; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; DNA SEQUENCE; ENZYME ACTIVITY; EPIGENETICS; ERYTHROPOIESIS; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HIGH THROUGHPUT SCREENING; HISTONE MODIFICATION; HUMAN; IMMUNOFLUORESCENCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; NONHUMAN; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; THERAPEUTIC USE;

DIABETES MELLITUS, TYPE 1; DNA METHYLATION; EPIGENESIS, GENETIC; GENOME, HUMAN; HISTONES; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 84925582031     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 34(Suppl 1):S62-S69, 2011.
2. Axelsson S, Chéramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E, Mallone R, Ludvigsson J, Casas R. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS One 6(12):e29008, 2011.
3. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 21(3):381-395, 2011.
4. Bell CG, TeschendorffAE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics 3:33, 2010.
5. Brandl A, Heinzel T, Krämer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell 101(4):193-205, 2009.
6. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164(1-2):10-21, 2005.
7. Chen YG, Silveira PA, Osborne MA, Chapman HD, Serreze DV. Cellular expression requirements for inhibition of type 1 diabetes by a dominantly protective major histocompatibility complex haplotype. Diabetes 56(2):424-430, 2007.
8. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35(1):89-96, 2005.
9. Chou DH, Bodycombe NE, Carrinski HA, Lewis TA, Clemons PA, Schreiber SL, Wagner BK. Small-Molecule Suppressors of Cytokine-Induced beta-Cell Apoptosis. ACS Chem Biol 5(8):729-734, 2010.
10. Çeti{dotless}n D, Unübol M, Karaoğlu AO, Meteoğlu I, Bozkurt G. Coexistence of type 1 diabetes mellitus and Crohn's disease. Turk J Gastroenterol 24(5):451-452, 2013.
11. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, GA. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
12. Cronin CC, Shanahan F. Insulin-dependent diabetes mellitus and coeliac disease. Lancet 349(9058):1096-1097, 1997.
13. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 25(10):1010-1022, 2011.
14. Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, Lehuen A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19(1):65-73, 2013.
15. Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist 18(5):619-624, 2013.
16. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370(Pt 3):737-749, 2003.
17. Duncan EM, Muratore-Schroeder TL, Cook RG, Garcia BA, Shabanowitz J, Hunt DF, Allis CD. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 135(2):284-294, 2008.
18. Dupré J, Stiller CR, Gent M, Donner A, von Graffenried B, Heinrichs D, Jenner M, Keown P, Mahon J, Martell R, et al. Clinical trials of cyclosporin in IDDM. Diabetes Care Suppl 1:37-44, 1988.
19. Eaves IA, Wicker LS, Ghandour G, Lyons PA, Peterson LB, Todd JA, Glynne RJ. Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of type 1 diabetes. Genome Res 12(2):232-243, 2002.
20. Eckenrode SE, Ruan Q, Yang P, Zheng W, McIndoe RA, She JX. Gene expression profiles define a key checkpoint for type 1 diabetes in NOD mice. Diabetes 53(2):366-375, 2004.
21. Elo LL, Mykkänen J, Nikula T, Järvenpää H, Simell S, Aittokallio T, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O, Lahesmaa R. Early suppression of immune response pathways characterizes children with prediabetes in genome-wide gene expression profiling. J Autoimmun 35(1):70-76, 2010.
22. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, Siegmund B. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176(8):5015-5022, 2006.
23. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363:15-23, 2005.
24. Gysemans C, Callewaert H, Overbergh L, Mathieu C. Cytokine signalling in the beta-cell: a dual role for IFNgamma. Biochem Soc Trans 36(Pt 3):328-333, 2008.
25. Harlan DM, Kenyon NS, Korsgren O, Roep BO. Immunology of Diabetes Society. Current advances and travails in islet transplantation. Diabetes 58(10):2175-2184, 2009.
26. Hasan S, Hottiger MO. Histone acetyl transferases: a role in DNA repair and DNA replication. J Mol Med (Berl) 80(8):463-474, 2002.
27. Haumaitre C, Lenoir O, Scharfmann R. Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol 28(20):6373-6383, 2008.
28. Herbelin A, Gombert JM, Lepault F, Bach JF, Chatenoud L. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 161(5):2620-2628, 1998.
29. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31(4):539-550, 2009.
30. Irie J, Reck B, Wu Y, Wicker LS, Howlett S, Rainbow D, Feingold E, Ridgway WM. Genome-wide microarray expression analysis of CD4+ T Cells from nonobese diabetic congenic mice identifies Cd55 (Daf1) and Acadl as candidate genes for type 1 diabetes. J Immunol 180(2):1071-1079, 2008.
31. Ize-Ludlow D, Lightfoot YL, Parker M, Xue S, Wasserfall C, Haller MJ, Schatz D, Becker DJ, Atkinson MA, Mathews CE. Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes 60(8):2086-2091, 2011.
32. Jayaraman S. Epigenetics of autoimmune diabetes. Epigenomics 3(5):639-648, 2011.
33. Jayaraman, S, Balasingh S, Exposito J, Ponte G, Baidal D, Cure P, Hafiz M, Meneghini L, Froud T, Alejandro R, Ricordi C. Patients with Type 1 diabetes display selective defect in antigen receptor mediated T cell apoptosis. Open J Biol Biochem 2012:1-2, 2012a.
34. Jayaraman S. Epigenetic mechanisms of metabolic memory in diabetes. Circ Res 110(8):1039-1041, 2012b.
35. Jayaraman S. T-bet in the spot light: roles in distinct T-cell fate determination. Cell Mol Immunol 10(4):289-291, 2013.
36. Jayaraman S, Patel A, Jayaraman A, Patel V, Holterman M, Prabhakar B. Transcriptome analysis of epigenetically modulated genome indicates signature genes in manifestation of type 1 diabetes and its prevention in NOD mice. PLoS One 8(1):e55074, 2013.
37. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532):1074-1080, 2001.
38. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 92(9):3705-3711, 2007.
39. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J Immunol 164(7):3919-3923, 2000.
40. Kleemann R, Bucala R. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010:610479, 2010.
41. Kulmala P, Savola K, Petersen JS, Vähäsalo P, Karjalainen J, Löppönen T, Dyrberg T, Akerblom HK, Knip M. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 101(2):327-336, 1998.
42. Larsen L, Tonnesen M, Ronn SG, Størling J, Jørgensen S, Mascagni P, Dinarello CA, Billestrup N, Mandrup-Poulsen T. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 50(4):779-789, 2007.
43. Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol 13(11):777-789, 2013.
44. Lee KU, Amano K, Yoon JW. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 37(7):989-991, 1988.
45. Lewis EC, Blaabjerg L, Størling J, Ronn SG, Mascagni P, Dinarello CA, Mandrup-Poulsen T. The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Mol Med 17(5-6):369-377, 2011.
46. Lugrin J, Ding XC, Le Roy D, Chanson AL, Sweep FC, Calandra T, Roger T. Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim Biophys Acta 1793(11):1749-1758, 2009.
47. Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T. Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 53(12):2569-2578, 2010.
48. Lundh M, Christensen DP, Damgaard Nielsen M, Richardson SJ, Dahllöf MS, Skovgaard T, Berthelsen J, Dinarello CA, Stevenazzi A, Mascagni P, Grunnet LG, Morgan NG, Mandrup-Poulsen T. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia 55(9):2421-2431, 2012.
49. McDevitt HO, Unanue ER. Autoimmune diabetes mellitus-much progress, but many challenges. Adv Immunol 100:1-12, 2008.
50. Mackay DJ, Temple IK. Transient neonatal diabetes mellitus type 1. Am J Med Genet C Semin Med Genet 154C(3):335-342, 2010.
51. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13(6):477-483, 2001.
52. Mfarrej B, Keir M, Dada S, Trikudanathan S, Sayegh MH, Sharpe AH, Guleria I. Anti-CD3 mAb treatment cures PDL1-/- NOD mice of diabetes but precipitates fatal myocarditis. Clin Immunol 140(1):47-53, 2011.
53. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38-51, 2006.
54. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 111(4):539-552, 2003.
55. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell 154(2):430-441, 2013.
56. Newell EW, Davis MM. Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol 32(2):149-157, 2014.
57. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin Immunol 149(3):279-285, 2013.
58. Patel T, Patel V, Singh R, Jayaraman S. Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol Cell Biol 89(5):640-649, 2011.
59. Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011:371832, 2011.
60. Rajput A, Singh B. Gene expression profiling in type 1 diabetes prone NOD mice immunized with a disease protective autoantigenic peptide. J Autoimmun 23(4):311-321, 2004.
61. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JL. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 118(7):2562-2573, 2008.
62. Reynier F, Pachot A, Paye M, Xu Q, Turrel-Davin F, Petit F, Hot A, Auffray C, Bendelac N, Nicolino M, Mougin B, Thivolet C. Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. Genes Immun 11(3):269-278, 2010.
63. Ridgway WM, Peterson LB, Todd JA, Rainbow DB, Healy B, Burren OS, Wicker LS. Gene-gene interactions in the NOD mouse model of type 1 diabetes. Adv Immunol 100:151-175, 2008.
64. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, AronoffS, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790):487-497, 2011.
65. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7):941-953, 2004.
66. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 28(5):1068-1076, 2005.
67. Sobel DO, Han J, Williams J, Yoon JW, Jun HS, Ahvazi B. Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse. J Autoimmun 19(3):129-137, 2002.
68. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F, Marrack P, Mahata SK, Kappler JW, Haskins K. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 11(3):225-231, 2010a.
69. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A 107(24):10978-10983, 2010b.
70. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64(2):435-459, 2000.
71. Strohman RC. Linear genetics, non-linear epigenetics: complementary approaches to understanding complex diseases. Integr Physiol Behav Sci 30(4):273-282, 1995.
72. Soutoglou E, Viollet B, Vaxillaire M, Yaniv M, Pontoglio M, Talianidis I. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J 20(8):1984-1992, 2001.
73. Takahashi I, Miyaji H, Yoshida T, Sato S, Mizukami T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J Antibiot (Tokyo) 49(5):453-457, 1996.
74. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37(11):1574-1582, 1988.
75. Todd JA. Etiology of type 1 diabetes. Immunity 23;32(4):457-467, 2010.
76. Tuller T, Atar S, Ruppin E, Gurevich M, Achiron A. Common and specific signatures of gene expression and protein-protein interactions in autoimmune diseases. Genes Immun 14(2):67-82, 2013.
77. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5(4-5):245-253, 1996.
78. Vantyghem MC, Defrance F, Quintin D, Leroy C, Raverdi V, Prévost G, Caiazzo R, Kerr-Conte J, Glowacki F, Hazzan M, Noel C, Pattou F; Diamenord; G4 working groups. Treating diabetes with islet transplantation: Lessons from the past decade in Lille. Diabetes Metab 40(2):108-119, 2014.